No Data
Shanghai Shen Lian Biomedical Gets China Approval for Pseudorabies Injection for Pigs
Shenlian Biotech: Report for the third quarter of 2024
Third Quarter Report 2024
Shanghai Shen Lian Biomedical Corporation: Intensified competition weakens the leading profit of pig vaccines, will expand new product development | Directly hit earnings conference
1. Affected by the sluggish downstream livestock breeding market and price decline, the leading pig vaccine maker Shanghai Shen Lian Biomedical Corporation experienced an increase in revenue but not in profit; 2. Nie Dongsheng stated at the earnings conference that in the second half of 2024, Shanghai Shen Lian Biomedical Corporation will timely adjust short-term, medium-term, and long-term operating goals, expand market development and global strategic layout of new products, including cattle and sheep foot-and-mouth disease inactivated vaccines, increase the sales proportion of pig circovirus vaccines, and at the same time, have products entering the supply chain system of multiple large-scale breeding groups.
Optimistic Investors Push Shanghai Shen Lian Biomedical Corporation (SHSE:688098) Shares Up 44% But Growth Is Lacking
Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. 2024 Semi-Annual Report
Pinning Down Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) P/S Is Difficult Right NowNo Data
No Data
